The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
Open accessThe DOI matches its Crossref record; 175 of the 177 references it cites were found in a registry or an index.
Abstract
Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages, and these activities are thought to be important mechanisms of action for many of these mAbs in vivo. Several mAbs also activate the classical complement pathway and promote complement-dependent cytotoxicity (CDC), although with very different levels of efficacy, depending on the mAb, the target antigen, and the tumor type. Recent studies have unraveled the various structural factors that define why some IgG1 mAbs are strong mediators of CDC, whereas others are not. The role of complement activation and membrane inhibitors expressed by tumor cells, most notably CD55 and CD59, has also been quite extensively studied, but how much these affect the resistance of tumors in vivo to IgG1 therapeutic mAbs still remains incompletely understood. Recent studies have demonstrated that complement activation has multiple effects beyond target cell lysis, affecting both innate and adaptive immunity mediated by soluble complement fragments, such as C3a and C5a, and by stimulating complement receptors expressed by immune cells, including NK cells, neutrophils, macrophages, T cells, and dendritic cells. Complement activation can enhance ADCC and ADCP and may contribute to the vaccine effect of mAbs. These different aspects of complement are also briefly reviewed in the specific context of FDA-approved therapeutic anti-cancer IgG1 mAbs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Epcoritamab is a subcutaneously administered bispecific antibody approved in numerous countries as monotherapy for follicular lymphoma after two or more lines of therapy.”
From Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Adverse events were manageable and consistent with the established safety profiles of the individual components of the triplet, 5,13,18 with no new safety findings.”
From Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (2026) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219
RetractedInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Complement System Part I – Molecular Mechanisms of Activation and Regulation
Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00262 · Cited by 1,620
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518 · cited 1×
“In some cases, the studies that have compared obinutuzumab with rituximab have shown a significant advantage of the former, particularly in CLL in combination with chlorambucil [166,167].”
ResultComplement System Part II: Role in Immunity
Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00257 · Cited by 1,051 · cited 1×
“On this basis, it should be clear that C9 polymerization generally correlates with effective cell lysis [30,32,33].”
Backgroundde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981 · cited 1×
“In contrast, obinutuzumab is only a weak complement activator [11,50] (a type II antibody).”
BackgroundKrejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954 · cited 2×
“Daratumumab and isatuximab have also been reported to deplete CD38+ immune regulatory cells, such as Treg, Breg, and myeloid derived suppressor cells (MDSCs) in vitro and in vivo [132,133].”
BackgroundProperties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847 · cited 1×
“The major caveat of studies in mice is that both complement and FcγRs differ considerably between mice and humans, and some complement inhibitory proteins are species specific, so that the relative roles of CDC, ADCC, and ADCP in mice may not fully recapitulate the human situation [74,136].”
Background
Research works printed but not linked: 2
- 5. Lindorfer, M.A.; Koehl, J.; Taylor, R.P. Interactions between the complement system and Fcgamma receptors. In IgG Fc: Linking Adaptive and Innate Immunity ; Nimmerhahn, F., Ackerman, M.E., Eds.; Elsevier Press: Amsterdam, The Netherlands, 2013; pp. 49-74.
- 165. Lindorfer, M.A.; Bakker, P.W.H.I.; Parren, P.W.; Taylor, R.P. Ofatumumab: A next-generation human therapeutic CD20 antibody with potent complement-dependent cytotoxicity. In Handbook of Therapeutic Antibodies ; Duebel, S., Reichert, J.M., Eds.; Wiley-VCH: Weinberg, Germany, 2013; pp. 1733-1744.
Cited by
A guide to complement biology, pathology and therapeutic opportunity
Mastellos, D. C., Hajishengallis, G., & Lambris, J. D. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00926-1 · Cited by 320
“For decades, complement activation was merely considered an auxiliary mechanism that potentiates the cytolytic action of tumour-specific antibodies through the process of complement-dependent cytotoxicity 14,135 .”
Cancer therapy with antibodies
Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., & Zhou, S. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00690-x · Cited by 248
“Thus, the IgG4 format probably protects PD1-expressing effector T cells from being inadvertently killed via ADCC or CDC.”
InfluentialMechanisms of Therapeutic Antitumor Monoclonal Antibodies
Tsao, L.-C., Force, J., & Hartman, Z. C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1109 · Cited by 198
“Moreover, this can result in the assembly of the membrane attack complex (MAC), which allows for direct cellular target destruction (12).”
BackgroundAdvances in antibody-based therapy in oncology
Zinn, S., Vazquez-Lombardi, R., Zimmermann, C., Sapra, P., Jermutus, L., & Christ, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00516-z · Cited by 184
Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies
Golay, J., Andrea, A. E., & Cattaneo, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929895 · Cited by 144
Self-citationRodríguez-Nava, C., Ortuño‐Pineda, C., Illades‐Aguiar, B., Flores‐Alfaro, E., Leyva‐Vázquez, M. A., Parra‐Rojas, I., Moral-Hernández, Ó. D., Vences-Velázquez, A., Cortés-Sarabia, K., & Alarcón‐Romero, L. D. C. (2023) · Biomedicines · doi:10.3390/biomedicines11061610 · Cited by 106
“which then enabled the binding of other complement factors until poly-C9 was attached to the target cell for the formation of the membrane-attack-complex (MAC) [77].”
BackgroundEmerging Trends in Immunotherapy for Cancer
Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 88
Leleu, X. P., Martin, T. G., Weisel, K. C., Schjesvold, F. H., Iida, S., Malavasi, F., Manier, S., Min, C., Ocio, E. M., Pawlyn, C., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04917-5 · Cited by 77
Delgado, S. R., Faissner, S., Linker, R. A., & Rammohan, K. W. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12007-3 · Cited by 76
“These factors have been hypothesized to result in the observed enhanced CDC compared with the other antibodies because of more efficient binding and deposition of complement system components at the target cell surface [48, 66, 70–72].”
BackgroundStrategies to enhance monoclonal antibody uptake and distribution in solid tumors
Bordeau, B. M., & Balthasar, J. P. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0704 · Cited by 58
Tsao, L.-C., Crosby, E. J., Trotter, T. N., Wei, J.-P., Wang, T., Yang, X. Y., Summers, A. N., Lei, G., Rabiola, C. A., Chodosh, L. A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155636 · Cited by 57
Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
Hernández-López, A., Téllez‐González, M. A., Mondragón‐Terán, P., & Meneses‐Acosta, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720692 · Cited by 54
GD2-targeting therapy: a comparative analysis of approaches and promising directions
Philippova, J., Shevchenko, J. A., & Sennikov, S. V. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371345 · Cited by 59
“In CDC, the classical complement pathway is activated with the formation of the membrane attack complex (MAC) and recruitment of NK-, T, NKT-cells, neutrophils, macrophages, and dendritic cells (48).”
BackgroundCombination Therapy as a Promising Way to Fight Oral Cancer
Silva, J. P. N., Pinto, B. F., Monteiro, L. S., Silva, P. M. A., & Bousbaa, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061653 · Cited by 55
Complement‐targeted therapeutics: Are we there yet, or just getting started?
Ricklin, D. (2024) · European Journal of Immunology · doi:10.1002/eji.202350816 · Cited by 54
“…mAb for cancer therapy already engage complement-dependent cytotoxicity as a critical effector arm to facilitate the immune-mediated elimination of cancer cells [117], and considerable effort is currently invested in antibody engineering to improve such effector functions (e.g. HexaBodies [118]).”
Senent, Y., Tavira, B., Pío, R., & Ajona, D. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215900 · Cited by 42
Tang, Y., & Cao, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030422 · Cited by 45
“These Fcdependent effector mechanisms are crucial for many marketed antibodies, especially for anti-tumor antibodies [231].”
BackgroundThe complement system in clinical oncology: Applications, limitations and challenges
Ajona, D., Cragg, M. S., & Pío, R. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2024.101921 · Cited by 34
“The proximity of the epitope to the target cell membrane, the density of the antigen, the orientation imposed by the epitope positioning and the antibody-mediated movement of the antigen across the membrane are all factors that significantly influence antibody-mediated complement activation [73].”
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02360-8 · Cited by 41
Diverse Functions of C4b-Binding Protein in Health and Disease
Werner, L. M., & Criss, A. K. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300333 · Cited by 35
Arimori, T., Mihara, E., Suzuki, H., Ohishi, T., Tanaka, T., Kaneko, M. K., Takagi, J., & Kato, Y. (2024) · Structure · doi:10.1016/j.str.2024.02.007 · Cited by 29
“We also investigated complement - dependent cytotoxicity (CDC) activities 48,49 of H 2 Mab-214-mG 2a -f and H 2 Mab-119-mG 2a -f against BT-474 cells.”
Shahapurmath, S., Sharannavar, B. R., & Koli, R. (2025) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2025.100218 · Cited by 30
Therapeutic antibodies in oncology: an immunopharmacological overview
Toledo‐Stuardo, K., Ribeiro, C. H., González‐Herrera, F., Matthies, D. J., Roy, M. S. L., Dietz-Vargas, C., Latorre, Y., Campos, I., Guerra, Y., Tello, S., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03814-2 · Cited by 30
“In this sense, once TmAbs bind to its target on the tumor cell, they can activate the classical pathway of the complement cascade and mediate CDC [8]; in addition, they can trigger ADCC, ADCP, ADCT, or a combination of these [10, 12].”
BackgroundBednarczyk, M., Medina‐Montano, C., Fittler, F. J., Stege, H. M., Roskamp, M., Kuske, M., Langer, C., Vahldieck, M., Montermann, E., Tubbe, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062869 · Cited by 25
“A nano-vaccine applied for tumor therapy should be decorated with a tumor-associated/specific surface protein in order to obtain antibodies that recognize malignant cells and confer antibodymediated cytotoxic effects [83,84].”
BackgroundDual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody
Gehlert, C. L., Rahmati, P., Boje, A. S., Winterberg, D., Krohn, S., Theocharis, T., Cappuzzello, E., Lux, A., Nimmerjahn, F., Ludwig, R. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957874 · Cited by 21
Complement regulators as novel targets for anti-cancer therapy: A comprehensive review
Saxena, R., Gottlin, E. B., Campa, M. J., He, Y.-W., & Patz, E. F. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101931 · Cited by 23
Overview of tumor immunotherapy based on approved drugs
Chen, Z., Hu, T., Zhou, J. Y., Gu, X., Chen, S., Qi, Q., & Wang, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122419 · Cited by 22
Neuroblastoma—A Review of Combination Immunotherapy
Pieniążek, B., Cencelewicz, K., Bździuch, P., Młynarczyk, Ł., Lejman, M., Zawitkowska, J., & Derwich, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147730 · Cited by 25
Ovcinnikovs, V., Dijkman, K., Zom, G. G., Beurskens, F. J. M., & Trouw, L. A. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2024.101922 · Cited by 25
The selection of variable regions affects effector mechanisms of IgA antibodies against CD20
Evers, M., Rösner, T., Dünkel, A., Jansen, J. H. M., Baumann, N., ten Broeke, T., Nederend, M., Eichholz, K. M., Klausz, K., Reiding, K. R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004598 · Cited by 17
Mausser, E., Nador, E., Politch, J. A., Pauly, M. R., Marathe, J. G., Moench, T. R., Zeitlin, L., Whaley, K. J., & Anderson, D. J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282147 · Cited by 18
Ishikawa, K., Suzuki, H., Ohishi, T., Nakamura, T., Yanaka, M., Li, G., Tanaka, T., Ohkoshi, A., Kawada, M., Kaneko, M. K., et al. (2024) · Oncology Reports · doi:10.3892/or.2024.8806 · Cited by 14
“The CDC is a crucial antitumor mechanism by mAbs (40,41).”
BackgroundT cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing
Besla, R., Penuel, E., Del Rosario, G., Cosino, E., Myrta, S., Dillon, M., Lazar, G. A., Nickles, D., Spiess, C., Yu, S.-F., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0072 · Cited by 13
Nakamura, A., Suzuki, S., Kanasugi, J., Ejiri, M., Hanamura, I., Ueda, R., Seto, M., & Takami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910761 · Cited by 14
Ibeanu, G. C., Rowaiye, A. B., Okoli, J., & Eze, D. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s486731 · Cited by 15
“141 Beyond antibody production, B-cells also act as APCs, an essential function in antitumor immunity.”
Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies
Hussain, K., Cragg, M. S., & Beers, S. A. (2021) · Cancers · doi:10.3390/cancers13194904 · Cited by 11
Yu, L., Zhou, Y. F., & Junzhi, W. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115397 · Cited by 10
Goldberg, B. S., Kaku, C. I., Dufloo, J., Bruel, T., Schwartz, O., Spencer, D. A., Hessell, A. J., & Ackerman, M. E. (2021) · mBio · doi:10.1128/mbio.01743-21 · Cited by 11
Monoclonal Antibodies in Oncology: A Decade of Novel Options
Kardile, V., Kulkarni, A., Nadar, B., & Saldanha, T. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01144-1 · Cited by 10
Sözen, S., & Emir, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104150 · Cited by 12
Suzuki, H., Ohishi, T., Tanaka, T., Kaneko, M. K., & Kato, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158386 · Cited by 17
“Complement-dependent cellular cytotoxicity (CDC) is also exerted by the Fc domain of mAbs [20,21].”
BackgroundSuzuki, H., Ohishi, T., Asano, T., Tanaka, T., Saito, M., Mizuno, T., Yoshikawa, T., Kawada, M., Kaneko, M. K., & Kato, Y. (2022) · Oncology Reports · doi:10.3892/or.2022.8366 · Cited by 10
“There was no differ‑ ence between H77Bf and control dog IgG about CDC against CHO‑K1 (Fig.”
InfluentialSuzuki, H., Ohishi, T., Tanaka, T., Kaneko, M. K., & Kato, Y. (2024) · Preprints.org · doi:10.20944/preprints202407.0864.v1 · Cited by 8
Noorkhajavi, G., Banakholdi, A., Torabi, A., Zoghi, A., Iranijam, E., & Safarzadeh, E. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04039-8 · Cited by 9
“2B) [42, 43], Antibody-Dependent Cellular Phagocytosis (ADCP) (Fig.”
A Short Update on the Use of Monoclonal Antibodies in COVID-19
Vitiello, A., Sabbatucci, M., Ponzo, A., Salzano, A., & Zovi, A. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00904-y · Cited by 6
“In fact, they induce complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and anti-body-dependent phagocytosis [13, 14].”
Antibody-Loaded Nanoplatforms for Colorectal Cancer Diagnosis and Treatment: An Update
Djermane, R., Nieto, C., Vega, M. A., & del Valle, E. M. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051514 · Cited by 8
Nguyen, N. T. B., Leung, H. W., Pang, K. T., Tay, S. J., Walsh, I., Choo, A. B. H., & Yang, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-42925-1 · Cited by 5
“Rituximab, an extensively used therapy for non-Hodgkin’s lymphoma, possesses the ability to eliminate malignant cells through various mechanisms, including cell death, CDC and ADCC by engaging Fc gamma receptors 31 .”
BackgroundMasuda, Y., Yamashita, S., Nakayama, Y., Shimizu, R., & Konishi, M. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00802 · Cited by 6
Hamers, S. M. W. R., Boyle, A. L., & Sharp, T. H. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400091 · Cited by 5
The role of complement in tumor immune tolerance and drug resistance: a double-edged sword
Yang, R., Fu, D., & Liao, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529184 · Cited by 7
Interdonato, A., Choblet, S., Sana, M., Valgardsdottir, R., Cribioli, S., Alzani, R., Roth, M., Cérutti, M., & Golay, J. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.07.012 · Cited by 5
Self-citationMontalvo-Castro, R. E., & Salinas-Jazmín, N. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m22000657 · Cited by 5
Bradl, M., Yu, Q., & Takai, Y. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101945 · Cited by 7
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions
Damiani, D., & Tiribelli, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104571 · Cited by 5
“Moreover, the IgG1 subclass can also bind the protein C1q, generated by complement activation, inducing cell death by complement-dependent cytotoxicity [55].”
Lai, P. S., Usama, S. M., Kiew, L. V., Lee, H. B., Chung, L. Y., Burgess, K., & Kue, C. S. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03147-y · Cited by 4
Stellabody: A novel hexamer‐promoting mutation for improved IgG potency
Whitehead, C. A., Wines, B. D., Davies, A. M., McDonnell, J. M., Trist, H. M., Esparon, S. E., & Hogarth, P. M. (2024) · Immunological Reviews · doi:10.1111/imr.13400 · Cited by 4
How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2+
Taylor, R. P., & Lindorfer, M. A. (2020) · Antibodies · doi:10.3390/antib9030045 · Cited by 4
Self-citationAdverse events of monoclonal antibodies use in therapy of hematological malignancies
Maksymowicz, M., & Podhorecka, M. (2022) · Hematology in Clinical Practice · doi:10.5603/hcp.2021.0014 · Cited by 3
Directed-Complement Activation as a Novel Immunotherapeutic Approach for HER2-Breast Cancer
Seguin‐Devaux, C., Brandus, B., Plesséria, J., Iserentant, G., Servais, J.-Y., Pitiot, A., Kanli, G., Behrmann, I., Schober, R., Zimmer, J., et al. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s517584 · Cited by 3
Azuly, H., Shafat, T., Grupel, D., Porges, T., Abuhasira, R., Belkin, A., Deri, O., Oster, Y., Zahran, S., Horwitz, E., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01089-9 · Cited by 3
“[25 , 26].”
The Basics of Large-Scale Commercial Production of Monoclonal Antibodies
Nikita, N., Rai, A., Verma, A., Sharma, R., Bisht, N., & Tandon, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-6270-5_3 · Cited by 3
Calafato, G., Bortolotti, M., Polito, L., & Bolognesi, A. (2025) · Toxins · doi:10.3390/toxins17060308 · Cited by 3
“It needs to be highlighted that the cytotoxic activity of our ITs was entirely due to RIPs, since in the experimental systems used, there were no cells of the immune system nor complement factors, which could induce ADCC or CDC, respectively [36].”
Amen, A., Thielens, N. M., Dumestre‐Pérard, C., & Clavarino, G. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102638 · Cited by 2
Pape, L. J., Gebhardt, A. J., Dannenberg, M., Risch, H., Duttmann, A., Weisel, K. C., Hambach, J., Koch‐Nolte, F., & Bannas, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-25194-y · Cited by 2
Takeuchi, S., Ito, Y., Matsuoka, S., ABE, M., Tsurui, H., Horimoto, Y., Fukuhara, T., Hirano, T., Mizutani, N., Ito, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-32892-0 · Cited by 2
Site-specific drug delivery utilizing monoclonal antibodies
Marson, D., Russi, M., Fermeglia, A., Laurini, E., & Pricl, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91668-4.00007-1 · Cited by 2
Eker, S. G., Yengin, G. I., Tatar, C., & Öktem, G. (2024) · Advances in experimental medicine and biology · doi:10.1007/5584_2024_838 · Cited by 5
Clinical Applications, Patents, and Challenges in Cancer Immunotherapy
Nanda, A., Kanhar, S., Singh, M. K., Akram, W., & Haider, T. (2024) · Springer eBooks · doi:10.1007/978-981-97-7022-9_18 · Cited by 2
Suzuki, H., Ohishi, T., Nanamiya, R., Kawada, M., Kaneko, M. K., & Kato, Y. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100488 · Cited by 1
“Moreover, the Fc domain of these mAbs can exert complement-dependent cytotoxicity (CDC) [17,18].”
BackgroundCytotoxicity mechanisms of passive anti-GD2 immunotherapy in pediatric tumors
Melnikov, M. E., Kulyova, S. A., Кондратьев, Г. В., Vasilyeva, M., & Savelieva, O. E. (2025) · Advances in molecular oncology · doi:10.17650/2313-805x-2025-12-2-47-57 · Cited by 3
Complement-mediated ADCP as a distinct and finite cytotoxic mechanism of monoclonal antibodies
Wagoner, C. M. V., Pinney, J. J., Sovinski, H., Ransegnola, B. P., Jaimes‐Delgadillo, N. C., Chu, C. C., Zent, C. S., & Elliott, M. R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1788948 · Cited by 1
“Previous studies have shown that antibody-mediated complement activation results in the deposition of complement fragments on target cells and subsequent induction of cADCP (23, 26, 32, 33, 38, 65, 66).”
Innate immunity and biomarkers of multiple sclerosis relapse versus remission
Karadeniz, M., Wesselingh, R., Jayakrishnan, P. C., Sequeira, R. P., van der Walt, A., Butzkueven, H., & Monif, M. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104058 · Cited by 1
Evolocumab-associated haemorrhagic pericarditis with cardiac tamponade: case report
Kim, A. Y., Bradel, L., Hossain, N. A., & Wong, B. C. (2026) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytag403 · Cited by 1
Wang, Y., He, S., Yang, H., Zhang, J., Yu, L., Xiong, J., Li, X., Qiu, J., & Ma, B. (2026) · Biology · doi:10.3390/biology15171472 · Cited by 1
“…antibody that mediates its effects primarily through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis in B cells [31]; thus, the observed in vitro responses are unlikely to reflect canonical CD20-dependent mechanisms.”
Membrane-Bound Complement Regulatory Proteins in Breast Cancer: Are They Best Therapeutic Targets?
Álvarez-Lorenzo, S., Montalvo-Castro, R. E., Jiménez-López, J., Medina-Mondragón, M. A., & Salinas-Jazmín, N. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109945 · Cited by 1
Hock, B. D., Goddard, L., MacPherson, S. A., Strother, R. M., Gibbs, D., Pearson, J. F., & McKenzie, J. L. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290793 · Cited by 1
Advancing Cancer Therapy: A Review of Recent Progress in Monoclonal Antibodies
Snehitha, B., Jyothsna, M., Sai, A. R., Sapkota, B., Revanth, B., Reddy, K. S., & Kumar, B. P. (2024) · Asian Journal of Advances in Research · doi:10.56557/ajoair/2024/v7i14046 · Cited by 1
Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapyPreprint
Seguin‐Devaux, C., Brandus, B., Plesséria, J., Iserentant, G., Servais, J.-Y., Kanli, G., Behrmann, I., Zimmer, J., Cohen, J. H. M., & Dervillez, X. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.02.578619 · Cited by 1
S, P. B. D., Nagaraja, S. B., & Niveditha (2021) · Indian Journal of Pharmacy and Pharmacology · doi:10.18231/j.ijpp.2021.025
Special Issue: The Role of Complement in Cancer Immunotherapy
Taylor, R. P. (2021) · Antibodies · doi:10.3390/antib10030029
“Zent and colleagues have made use of a bedside to bench approach and find that phagocytosis of opsonized cells by macrophages appears to be the principal and most important mechanism by which B cells opsonized with rituximab or ofatumaub are eliminated [2].”
BackgroundResultSelf-citationMarzouq, M., Alshammary, A. F., Bourguiba, S., Raslan, W., Ashoor, D., & Fathallah, M. D. (2021) · Research Square · doi:10.21203/rs.3.rs-1132248/v1
Montalvo-Castro, R. E., & Salinas-Jazmín, N. (2022) · Gaceta Médica de México · doi:10.24875/gmm.22000004
Development of Next-Generation Antibody Therapeutics Using DDS and Molecular Imaging
Yasunaga, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_200-1
Generalov, R., Fiorito, E., Foss, S., Pascal, V., Heyerdahl, H., Repetto‐Llamazares, A. H. V., Andersen, J. T., Tjønnfjord, G. E., Skånland, S. S., & Dahle, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.12.548667
“CDC data were in line with previously reported observations for DHXBD37 (29), 6 ofatumumab, and rituximab (29, 48).”
ResultÁlvarez-Lorenzo, S., & Salinas-Jazmín, N. (2022) · Revista de Farmacología · doi:10.58713/rf.v1i2.1
Ishikawa, K., Suzuki, H., Ohishi, T., Ohkoshi, A., Kaneko, M. K., Katori, Y., & Kato, Y. (2024) · Preprints.org · doi:10.20944/preprints202403.1500.v1
Types of Immunotherapy, Mechanism of Action and Side Effects
Sahip, B., Ertop, Ş., Ak, M. A., & Ayağ, H. (2024) · doi:10.69860/nobel.9786053359388.2
Multi‐Specific Binding Strategy
Zhou, Y., Xu, S., Ding, D., Tang, K., Liu, X., Kim, M., & Zhan, P. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch11
Genotoxic chemotherapy impedes complement dependent cytotoxicity via Chk1-mediated CD59 regulationPreprint
Chan, A. S. Y., Anbuselvan, A., Jaynes, P. W., Ong, C., Hoppe, M. M., Yong, W. K., Khanchandani, V., Lee, J. M., Mustafa, N. B., Azaman, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.17.638751
“In preclinical and clinical settings, blockade of these mCRPs has been shown to enhance CDC and improve therapeutic efficacy (20,21).”
Park, C., Kwak, J., Lim, S. Y., Kim, H., & Lim, K. S. (2025) · KSBB Journal · doi:10.7841/ksbbj.2025.40.1.22
Gonzalez, E., Kreger, J., Liu, Y., Wu, X., Barbetta, A., Baugh, A. G., Al-Zubeidy, B., Jang, J. K., Shin, S. M., Jacobo, M. B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.09.658361 · Cited by 3
“Furthermore, we found evidence that EPC drives an antibody class switching to IgG1, likely via stimulation of a Th2 response, which could lead to the elimination via NK cells and macrophages expressing IgG-specific FcR receptors 60 .”
Wang, Y., & Wang, X. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01808-7
“This protein is a potent inhibitor of the complement membrane attack complex [33].”
Development of Next-Generation Antibody Therapeutics Using DDS and Molecular Imaging
Yasunaga, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_200
Jiao, D., Hu, Y., Liao, L., Zhang, H., Wang, L., Xiao, Y., & Tian, J. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.117229
Giedraityte, Z., Aarnio, N., Mohamed, F. A. N., Bjørge, L., & Meri, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-30099-x
“…immunotherapy tumor killer system is to harness the patient’s own effector mechanisms such as antibody-dependent cellular toxicity (ADCC), direct complement-mediated killing (CDC), complement-dependent cellular cytotoxicity (CDCC), or the complement system to destroy malignant cells 31–35 .”
Mechanism of action of isatuximab in multiple myeloma. Literature review and clinical observation
Soloveva, M. V., Solovev, M. V., & Менделеева, Л. П. (2026) · Oncohematology · doi:10.17650/1818-8346-2026-21-1-59-65
Advantages of targeted nanomedicine in cancer treatment
Misra, S. K., & Pathak, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44579-8.00008-4
McCormick, A. L., Esfahani, B. G., Page, C. K., Shepard, J. D., Vidal, A. G. J., McCaffrey, K. D., Lee, F. K., Tompkins, S. M., Vidal, J. E., & Mousa, J. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.28.728567
“31,32 To assess the ability of mAb 5995-40 to promote complement activation, complement deposition was measured following mAb 5995-40 binding to two choline-binding proteins, PspC and LytA proteins, by flow cytometry.”
Metadata
- Authors
- Golay, J., & Taylor, R. P.
- Affiliations
- Ospedale Papa Giovanni XXIII (IT)
- University of Virginia (US)
- Corresponding author
- Golay, Josée
- Taylor, Ronald P.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2020-10-28
- Volume
- 9
- Issue
- 4
- Pages
- 58
- ISSN
- 2073-4468 (ISSN-L)
- PMC
- PMC7709112
- OpenAlex
- W3097855394
- Cited by
- 104
- References
- 177
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 28 · 2023: 18 · 2022: 13 · 2021: 13 · 2020: 1
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Antibodies (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (IG19036, 5x1000 ISM)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- complement activation, IgG1, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, complement-dependent cytotoxicity, classical complement pathway, CD55, CD59, complement receptors, C3a, C5a, natural killer cells, macrophages
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.